News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News September 24, 2026
Gibson Dunn Advised WndrCo on Investment in HYROX
Gibson Dunn advised WndrCo on its co-investment in HYROX alongside L Catterton, in connection with the acquisition of Infront’s majority stake in HYROX in partnership with the HYROX founders.
Publications August 6, 2026
Biopharma M&A: Mid-Cap Public-Target Market Survey (First-Half 2026)
In the first six months of 2026, acquirers announced 13 qualifying acquisitions of public biopharma targets worth $66.6 billion in upfront consideration.
Publications August 5, 2026
Contingent Value Rights: A Drafting Guide for Biopharma M&A
Contingent value rights have become a defining feature of biopharma M&A, appearing in under 10% of mid-cap public-target deals before 2019 but a quarter to a third of them in every year since 2023.
Firm News July 29, 2026
Gibson Dunn Advised on Sale of TRIXIE
Gibson Dunn advised founder and majority shareholder Bonnik Hansen on the sale of TRIXIE Heimtierbedarf GmbH & Co. KG to Central Garden & Pet Company.
Firm News July 10, 2026
Gibson Dunn Advised Lone Star on €1.85 Billion Sale of Xella to Holcim
Gibson Dunn advised Lone Star on the €1.85 billion sale of Xella, a European leader in sustainable and innovative walling systems headquartered in Germany, to Holcim, the Swiss-listed leader in sustainable construction.
Accolades June 18, 2026
Twenty-eight Gibson Dunn Lawyers Recognized by Best Lawyers – Germany
Eighteen Gibson Dunn lawyers from our Frankfurt and Munich offices have been recognized in The Best Lawyers in Germany™ 2027 for their respective practice areas, while an additional ten have been included in The Best Lawyers: Ones to Watch in Germany™ 2027.
Firm News February 27, 2026
Gibson Dunn Advises Shareholders in Connection with Sale of Aicuris to Asahi Kasei
Gibson Dunn advised the shareholders in connection with the sale of Aicuris Anti-infective Cures AG to Asahi Kasei, through its subsidiary Veloxis Pharmaceuticals, Inc. The acquisition price amounts to 780 million euros (approximately $920 million USD).
Accolades February 20, 2026
Gibson Dunn Earns 13 Total Rankings in Chambers Germany 2026
Gibson Dunn has earned 13 total rankings in the 2026 edition of Chambers Germany – four firm practice group rankings and nine individual rankings, including a Band 1 ranking for Benno Schwarz. The